VBL Therapeutics’ Investigational Drug Ofra-Vec Fails Phase 3 Trial

VBL Therapeutics’ investigational drug ofra-vec (ofranergene obadenovec; VB-111) failed to show promise in a late-stage study for treatment of platinum-resistant ovarian cancer.

In the phase 3 trial, the combined ofra-vec plus paclitaxel treatment did not show meaningful improvements in progression-free survival and overall survival, the study’s primary endpoints.

VBL has decided to discontinue the study and shift its focus to ongoing phase 2 clinical trials to determine ofra-vec’s possible uses in metastatic colorectal cancer and recurrent glioblastoma multiforme.

“Given the urgent unmet need for those fighting platinum-resistant ovarian cancer, we are deeply disappointed that the top-line data indicate that ofra-vec did not improve progression free survival or overall survival,” said VBL CEO Dror Harats.